Blueberries Medical Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Facundo Garretón
- Full Time Employees
- 51
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 8500 West Georgia Street Toronto BC Canada V6C 3E8
- IPO Date
- Feb 6, 2019
- Website
- blueberriesmed.com
- Similar Companies
- Business
- Blueberries Medical Corp. (CSE: BBM), a Colombia-based licensed producer of medicinal cannabis and plant-derived bioactives founded in 2013 and headquartered in Bogotá, engages in the cultivation, extraction, manufacturing, and distribution of pharmaceutical-grade cannabis derivatives including CBD isolates, THC oils and distillates, premium medical flowers, water-soluble specialties, food-grade extracts, and magistral formulas; alongside functional supplements, wellness products, botanical ingredients, and natural health solutions targeting pharmaceutical, nutraceutical, and consumer markets in Colombia, Peru, and international regions. As a key operating subsidiary within Terraflos Inc., the company leverages advanced extraction technologies and GACP-certified third-party cultivation partnerships to supply standardized active pharmaceutical ingredients for functional foods, supplements, and skincare, while holding comprehensive Colombian licenses for psychoactive and non-psychoactive cannabis production, domestic commercialization, and export through its wholly owned subsidiary Blueberries SAS. Recent developments include regulatory approval in February 2025 for commercial pharmaceutical-grade THC supply, closure of a C$1.06 million CEO-led non-brokered private placement in March 2025 to fund operational expansion and working capital, advancement of technical validations with pharmaceutical clients and preparations to resume exports to Peru, strategic diversification into food tech and biotechnology-based products beyond core cannabis operations, and a shift to an asset-light model emphasizing recurring high-margin derivative sales.
Company News
Blueberries Medical Announces Closing of C$1.1 Million Non-Brokered Private Placement
Blueberries Medical Announces C$1.1 Million Non-Brokered Private Placement
Blueberries Medical Announces C$1 Million Non-Brokered Private Placement
Blueberries Medical Announces C$1 Million Non-Brokered Private Placement
Blueberries Medical Announces Closing of C$2 Million Non-Brokered Private Placement
Blueberries Medical Announces C$2 Million Non-Brokered Private Placement
Blueberries Medical Announces that its wholly subsidiary Blueberries SAS at Bogota, Colombia has made one of the biggest exports of Premium CBD Full Spectrum Oil of all time, scaling up its business to a level that will improve life condition of more than 2.500 patients in Peru
Blueberries Announces Webcast Instructions for its Annual General and Meeting (“AGM”)
Blueberries Medical Announces Closing of C$ 2.1 Million Non-Brokered Private Placement and the Appointment of New Director
Blueberries Medical Reports 2021 Q2 Financial Results and Provides Corporate and Operations Update
Blueberries Medical Reports 2021 Q1 Financial Results and Provides Corporate and Operations Update
Blueberries Medical Reports 2020 Financial Results
Blueberries Medical Signs Framework Agreement with YVY Life Sciences of Uruguay
Blueberries Medical Enters Growing Peruvian Medical Cannabis Market: Enters Binding LOI with Futura Farms
Blueberries Medical Appoints Former Clever Leaves Global Head of B2B as President of Latin American Operations
Blueberries Medical Closes $1M Strategic Financing Led by a Leading Latin American Private Equity Group with Extensive International Cannabis Industry Expertise; Appoints Facundo Garretón as Chairman & Interim CEO
Blueberries Medical Announces Closing of the Acquisition of BBV Labs – A Milestone in its Argentina Project